Benefits versus risk profile of buparlisib for the treatment of breast cancer

References

• Gobbini E, Ezzalfani M, Dieras V, et al. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. Eur J Cancer Oxf Engl 1990. 2018;96:17–24.
   PubMed Web of Science ®Google Scholar
• Swain SM, Kim S-B, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461–471.
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–439.
   PubMed Web of Science ®Google Scholar
• Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550–562.
   PubMed Web of Science ®Google Scholar
• Miller TW, Rexer BN, Garrett JT, et al. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res BCR. 2011;13(6):224.
   PubMed Web of Science ®Google Scholar
• López-Knowles E, O’Toole SA, McNeil CM, et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer. 2010 1;126(5):1121–1131.
   PubMed Web of Science ®Google Scholar
• Madsen RR, Vanhaesebroeck B, Semple RK. Cancer-associated PIK3CA mutations in overgrowth disorders. Trends Mol Med. 2018;24(10):856–870.
   PubMed Web of Science ®Google Scholar
• Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018 15;379(20):1926–1936.
   PubMed Web of Science ®Google Scholar
• Razavi P, Chang MT, Xu G, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018 Sep 10;34(3):427–438.e6.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Lazar AA, Bondarenko I, et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2013 10;31(2):195–202.
   PubMed Web of Science ®Google Scholar
• Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol Off J Am Soc Clin Oncol. 2012 1;30(22):2718–2724.
   PubMed Web of Science ®Google Scholar
• Abstract GS2-07: MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer. Cancer Research [Internet]. [ cited 2019 Mar 3]. Available from: http://cancerres.aacrjournals.org/content/78/4_Supplement/GS2-07
   Google Scholar
• Hurvitz SA, Andre F, Jiang Z, et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol. 2015;16(7):816–829.
   PubMed Web of Science ®Google Scholar
• André F, O’Regan R, Ozguroglu M, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15(6):580–591.
   PubMed Web of Science ®Google Scholar
• André F, Hurvitz S, Fasolo A, et al. Molecular alterations and everolimus efficacy in human epidermal growth factor receptor 2-overexpressing metastatic breast cancers: combined exploratory biomarker analysis from BOLERO-1 and BOLERO-3. J Clin Oncol Off J Am Soc Clin Oncol. 2016 20;34(18):2115–2124.
   PubMed Web of Science ®Google Scholar
• Krop IE, Mayer IA, Ganju V, et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17(6):811–821.
   PubMed Web of Science ®Google Scholar
• Tamura K, Kodaira M, Shimizu C, et al. Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer. Cancer Sci. 2018;109(5):1592–1601.
   PubMed Web of Science ®Google Scholar
• LBA10_PR Saura C. et al. Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC).
   Google Scholar
• Baselga J, Cortés J, DeLaurentiis M, et al. SANDPIPER: phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors. J Clin Oncol. 2017 20;35(15_suppl):TPS1119–TPS1119.
   Google Scholar
•  Abstract LBA3_André et al. PR ‘Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the Phase 3 SOLAR-1 trial’ Annals of Oncology, Volume 29 Supplement 8 October 2018.
   Google Scholar
• Rodon J, Dienstmann R, Serra V, et al. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013;10(3):143–153.
   PubMed Web of Science ®Google Scholar
• Maira S-M, Pecchi S, Huang A, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther. 2012;11(2):317–328.
   PubMed Web of Science ®Google Scholar
• O’Brien NA, McDonald K, Tong L, et al. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT. Clin Cancer Res Off J Am Assoc Cancer Res. 2014 1;20(13):3507–3520.
   PubMed Web of Science ®Google Scholar
• Bendell JC, Rodon J, Burris HA, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2012 20;30(3):282–290.
   PubMed Web of Science ®Google Scholar
• Robert M, Frenel J-S, Bourbouloux E, et al. Efficacy of buparlisib in treating breast cancer. Expert Opin Pharmacother. 2017;18(18):2007–2016.
   PubMed Web of Science ®Google Scholar
• Juvekar A, Burga LN, Hu H, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2012;2(11):1048–1063.
   PubMed Web of Science ®Google Scholar
• Alderton GK. Therapeutics: PI3K-PARP combination. Nat Rev Cancer. 2012;12(10):658.
   PubMed Web of Science ®Google Scholar
• Ibrahim YH, García-García C, Serra V, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012;2(11):1036–1047.
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Wulf GM, Barry WT, et al. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2017 01;28(3):512–518.
   PubMed Web of Science ®Google Scholar
• Chu CM, Schuler M, De Braud FGM. Dose-escalation study of sonidegib (LDE225) plus buparlisib (BKM120) in patients (pts) with advanced solid tumors. Esmo. 2014;25 (suppl_4): iv146-iv164. 10.1093/annonc/mdu331.
   Google Scholar
• Bedard PL, Tabernero J, Janku F, et al. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2015 Feb 15;21(4):730–738.
   PubMed Web of Science ®Google Scholar
• Ma CX, Luo J, Naughton M, et al. A phase i trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive metastatic breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2016 1;22(7):1583–1591.
   PubMed Web of Science ®Google Scholar
• Mayer IA, Abramson VG, Isakoff SJ, et al. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 20 Apr 2014;32(12):1202-1209
   Google Scholar
• Baselga J, Im S-A, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(7):904–916.
   PubMed Web of Science ®Google Scholar
• Campone M, Im S-A, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: overall survival results from BELLE-2. Eur J Cancer Oxf Engl. 1990;2018(103):147–154.
   Google Scholar
• Di Leo A, Johnston S, Lee KS, et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(1):87–100.
   PubMed Web of Science ®Google Scholar
• McRee AJ, Marcom PK, Moore DT, et al. A phase I trial of the PI3K inhibitor buparlisib combined with capecitabine in patients with metastatic breast cancer. Clin Breast Cancer. 2018;18(4):289–297.
   PubMed Web of Science ®Google Scholar
• Martín M, Chan A, Dirix L, et al. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4). Ann Oncol Off J Eur Soc Med Oncol. 2017 01;28(2):313–320.
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortés J, Im S-A, et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 20 Nov 2014;32(33):3753–3761.
   Google Scholar
• Saura C, Bendell J, Jerusalem G, et al. Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy. Clin Cancer Res Off J Am Assoc Cancer Res. 1 Apr 2014;20(7):1935–1945.
   Google Scholar
• Pistilli B, Pluard T, Urruticoechea A, et al. Phase II study of buparlisib (bkm120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy. Breast Cancer Res Treat. 2018;168(2):357–364.
   PubMed Web of Science ®Google Scholar
• Zambrano C, Schuler MH, Machiels JPH, et al. Phase Ib study of buparlisib (BKM120) plus either paclitaxel in Advanced solid tumor or paclitaxel + trastuzumab in HER2+ breast cancer. J Clin Oncol. 2014;32(suppl; abstr 627):5s.
   PubMedGoogle Scholar
• Guerin M, Rezai K, Isambert N, et al. PIKHER2: A phase Ib study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. Eur J Cancer Oxf Engl. 1990;2017(86):28–36.
   Google Scholar
• Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. JClin Oncol Off JAm SocClinOncol. 1 Mar 2010;28(7):1124–1130.
   Google Scholar
• Loibl S, de la Pena L, Nekljudova V, et al. Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). Eur J Cancer Oxf Engl. 1990;2017(85):133‑45.
   Google Scholar
• Busaidy NL, Farooki A, Dowlati A, et al. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol off J Am Soc Clin Oncol. 2012;30(23):2919–2928.
   PubMed Web of Science ®Google Scholar
• Juric D, Janku F, Rodón J, et al. Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor-positive advanced breast cancer: A phase 1b clinical trial. JAMA Oncol. 2018;13:e184475.
   Google Scholar
• Ackermann TF, Hörtnagl H, Wolfer DP, et al. Phosphatidylinositide dependent kinase deficiency increases anxiety and decreases GABA and serotonin abundance in the amygdala. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2008;22(5–6):735–744.
   PubMed Web of Science ®Google Scholar
• Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol off J Am Soc Clin Oncol. 2008;26(10):1664–1670.
   PubMed Web of Science ®Google Scholar
• Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet Lond Engl. 2016;388(10063):2997–3005.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast Edinb Scotl. 2017;31:244–259.
   PubMed Web of Science ®Google Scholar
• Campone M, Bachelot T, Gnant M, et al. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur J Cancer Oxf Engl 1990. 2013;49(12):2621–2632.
   PubMed Web of Science ®Google Scholar